• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    BeiGene Announces First Quarter 2025 Financial Results and Business Updates

    5/7/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONC alert in real time by email
    • First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024
    • Achieved GAAP profitability and significantly improved operating cash flow
    • Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26
    • Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland

    BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

    "We delivered another exceptional quarter, achieving our first quarter of GAAP profitability with continued global revenue growth. In the U.S., BRUKINSA remains the leader in new chronic lymphocytic leukemia (CLL) patient starts across all lines of therapy, and for the first time has become the overall BTKi market share leader," said John V. Oyler, Co-Founder, Chairman, and CEO of BeiGene. "We've made significant strides across our late-stage hematology and solid tumor pipelines, with multiple proof-of-concept readouts expected this year across our broad portfolio of antibody-drug conjugates, multispecific antibodies and targeted protein degraders. With accelerating financial momentum and a diversified global footprint spanning six continents, we are well positioned — as we transition to BeOne Medicines and redomicile to Switzerland — to become one of the world's most impactful oncology innovators."

    First Quarter 2025 Financial Snapshot

    (Amounts in thousands of U.S. dollars and unaudited)

     

     

    Three Months Ended March 31,

     

     

     

     

    2025

     

    2024

     

    % Change

    Net product revenues

     

    $1,108,530

     

    $746,918

     

    48%

    Net revenue from collaborations

     

    $8,749

     

    $4,734

     

    85%

    Total revenue

     

    $1,117,279

     

    $751,652

     

    49%

     

     

     

     

     

     

     

    GAAP income (loss) from operations

     

    $11,102

     

    $(261,348)

     

    104%

    Adjusted income (loss) from operations*

     

    $139,357

     

    $(147,341)

     

    195%

     

     

     

     

     

     

     

    GAAP net income (loss)

     

    $1,270

     

    $(251,150)

     

    101%

    Adjusted net income (loss)*

     

    $136,137

     

    $(145,896)

     

    193%

     

     

     

     

     

     

     

    GAAP basic EPS per ADS

     

    $0.01

     

    $(2.41)

     

    100%

    Adjusted basic EPS per ADS*

     

    $1.27

     

    $(1.40)

     

    191%

     

     

     

     

     

     

     

    GAAP diluted EPS per ADS

     

    $0.01

     

    $(2.41)

     

    100%

    Adjusted diluted EPS per ADS*

     

    $1.22

     

    $(1.40)

     

    187%

    * For an explanation of our use of non-GAAP financial measures refer to the "Note Regarding Use of Non-GAAP Financial Measures" section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release.

    First Quarter 2025 Financial Results

    Revenue for the first quarter of 2025 was $1.1 billion, compared to $752 million in the prior-year period driven primarily by growth in BRUKINSA product sales in the U.S. and Europe.

    Product Revenue totaled $1.1 billion for the first quarter of 2025 compared to $747 million in the prior-year period. The increase in product revenue was primarily attributable to increased sales of BRUKINSA. The U.S. continued to be the Company's largest market, with product revenue of $563 million compared to $351 million in the prior-year period. In-licensed products from Amgen and TEVIMBRA also contributed to product revenue growth.

    • U.S. sales of BRUKINSA totaled $563 million in the first quarter of 2025, representing growth of 60% over the prior-year period driven primarily by demand, with more than 60% of the quarter-over-quarter growth coming from expanded use in CLL as BRUKINSA continued to gain share as the leader in new patient starts in the U.S. in CLL and all other approved indications; BRUKINSA sales in Europe totaled $116 million in the first quarter of 2025, representing growth of 73% compared to the prior-year period, driven by increased market share across all major European markets, including Germany, Italy, Spain, France and the UK.
    • Sales of TEVIMBRA totaled $171 million in the first quarter of 2025, representing growth of 18% compared to the prior-year period.

    Gross Margin as a percentage of global product sales for the first quarter of 2025 was 85.1% compared to 83.3% in the prior-year period on a GAAP basis. The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in our portfolio. Gross margins also benefited from cost of sales productivity improvements for both BRUKINSA and TEVIMBRA. On an adjusted basis, which does not include depreciation and amortization, gross margin as a percentage of product sales increased to 85.5% for the first quarter of 2025, compared to 83.7% in the prior-year period.

    Operating Expenses

    The following table summarizes operating expenses for the first quarter of 2025:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    GAAP

     

     

     

    Non-GAAP

     

     

    (unaudited, in thousands, except percentages)

     

    Q1 2025

     

    Q1 2024

     

    % Change

     

    Q1 2025

     

    Q1 2024

     

    % Change

    Research and development

     

    $481,887

     

    $460,638

     

    5%

     

    $421,195

     

    $405,440

     

    4%

    Selling, general and administrative

     

    $459,288

     

    $427,427

     

    7%

     

    $395,511

     

    $372,146

     

    6%

    Total operating expenses

     

    $941,175

     

    $888,065

     

    6%

     

    $816,706

     

    $777,586

     

    5%

    Research and Development (R&D) Expenses increased for the first quarter of 2025 compared to the prior-year period on both a GAAP and adjusted basis primarily due to advancing preclinical programs into the clinic and early clinical programs into late stage. Upfront fees and milestone payments related to in-process R&D for in-licensed assets totaled nil and $35 million in the first quarter of 2025 and 2024, respectively.

    Selling, General and Administrative (SG&A) Expenses increased for the first quarter of 2025 compared to the prior-year period on both a GAAP and adjusted basis due to continued investment in the global commercial expansion of BRUKINSA primarily in the U.S. and Europe. SG&A expenses as a percentage of product sales were 41% for the first quarter of 2025, compared to 57% in the prior-year period.

    Net Income/(Loss) and Earnings Per Share

    GAAP net income improved for the first quarter of 2025, as compared to the prior-year period loss, primarily attributable to revenue growth and improved operating leverage.

    For the first quarter of 2025, both basic and diluted earnings per share was $0.00 per share and $0.01 per American Depositary Share (ADS), respectively, compared to basic loss of $0.19 per share and $2.41 per ADS in the prior-year period.

    Cash Provided by Operations for the first quarter of 2025 was $44 million, an increase of $353 million over the prior-year period.

    For further details on BeiGene's First Quarter 2025 Financial Statements, please see BeiGene's Quarterly Report on Form 10-Q for the first quarter of 2025 filed with the U.S. Securities and Exchange Commission.

    Full Year 2025 Guidance

    BeiGene is maintaining its full year 2025 revenue and expense guidance. Guidance is summarized below:

     

     

     

    FY 20251

    Total Revenue

    $4.9 billion to $5.3 billion

    GAAP Operating Expenses (R&D and SG&A)

    $4.1 billion to $4.4 billion

     

     

    Additional:

    GAAP Gross Margin Percentage in mid-80% range

     

    Positive Full Year GAAP Operating Income

    Generation of Positive Cash Flow from Operations

     

     

     

    1 Does not assume any potential new, material business development activity or unusual/non-recurring items. Assumes January 31, 2025 foreign exchange rates.

    BeiGene's total revenue guidance for full year 2025 of $4.9 billion to $5.3 billion includes expectations for strong revenue growth driven by BRUKINSA's U.S. leadership position and continued global expansion in both Europe and other important rest of world markets. Gross margin percentage is expected to be in the mid-80% range due to mix and production efficiencies as compared to 2024. BeiGene's guidance for combined operating expenses on a GAAP basis includes expectations of investment to support growth in both commercial and research at a pace that continues to deliver meaningful operating leverage. Non-GAAP operating expenses, which exclude costs related to share-based compensation, depreciation and amortization expense, are expected to track with GAAP operating expenses, with reconciling items unchanged from existing practice. Operating expense guidance does not assume any potential new, material business development activity or unusual/non-recurring items.

    First Quarter Business Highlights

    Core Marketed Products

    BRUKINSA

    • BRUKINSA is now approved in 75 markets globally with 11 new or expanded reimbursements in the quarter, including in Japan, Europe and Brazil.
    • Received approval for the addition of Siegfried in Switzerland as an alternate Drug Substance manufacturer by the European Medicines Agency.

    TEVIMBRA

    • TEVIMBRA is now approved in 46 markets globally with 11 new reimbursements in the quarter, including in the U.S., Europe and China.
    • Received U.S. Food and Drug Administration (FDA) approval in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1).
    • Received FDA approval for 150 mg Q2W and 300 mg Q4W alternate dosing regimens in addition to the already approved 200 mg Q3W dosing.
    • Received Japan approval in combination with platinum-containing chemotherapy for the first- and second-line treatment of adult patients with unresectable or metastatic ESCC.
    • Received European Commission approval in combination with etoposide and platinum chemotherapy as a first-line treatment for adult patients with extensive-stage small cell lung cancer.

    Select Clinical-Stage Programs

    Hematology

    • Sonrotoclax (BCL2 inhibitor): Continued enrollment of global Phase 2 trial for the treatment of Waldenström's macroglobulinemia.
    • Sonrotoclax BGB-11417-202: Filed in China for the treatment of relapsed/refractory (R/R) CLL.
    • Sonrotoclax CELESTIAL-RR MCL BGB-11417-302: Achieved first subject enrolled for Phase 3 trial for the treatment of R/R MCL.
    • Sonrotoclax CELESTIAL-TN CLL BGB-11417-301: Achieved last subject enrolled for Phase 3 trial for the treatment of treatment-naïve (TN) CLL.
    • BGB-16673 (BTK CDAC): Continued enrollment of potentially registration enabling Phase 2 trial for the treatment of R/R CLL with data readout expected in 2026.
    • BGB-16673: Initiated Phase 3 trial compared to physician's choice (IR/VR/BR) for treatment of R/R CLL.

    Lung Cancer

    • Tarlatamab (AMG757, DLL3xCD3 BiTE): Announced positive data readout from Phase 3 trial for the treatment of second-line small cell lung cancer in collaboration with Amgen.
    • Anti-TIGIT antibody: Discontinued clinical development of ociperlimab as a potential treatment for lung cancer.

    Anticipated R&D Milestones

    • The Company will hold an Investor R&D Day on June 26 highlighting its emerging breast cancer franchise and broader solid tumor portfolio.

    Programs

    Milestones

    Timing

    BRUKINSA

    • Tablet formulation: FDA and European Commission approvals.

    2H 2025

     

    • MANGROVE trial for TN MCL: Interim analysis of Phase 3 trial.

    2H 2025

     

    • MAHOGANY trial for the treatment of R/R follicular lymphoma: Complete enrollment of the FL portion of Phase 3 trial.

    2H 2025

    TEVIMBRA

    • EU approvals for the treatment of:

     

     

    • Neoadjuvant/adjuvant non-small cell lung cancer.

    1H 2025

     

    • First-line nasopharyngeal carcinoma.

    2H 2025

     

    • Subcutaneous formulation: Initiate Phase 3 trial.

    2H 2025

    Hematology

    • Sonrotoclax in combination with anti-CD20 antibody for the treatment of R/R CLL:

      First subject enrolled in global Phase 3 trial.

    1H 2025

     

    • Sonrotoclax for the treatment of R/R MCL: Data readout of Phase 2 trial and potential global accelerated approval submissions.

    2H 2025

     

    • BGB-16673 compared to noncovalent BTK inhibitor pirtobrutinib for the treatment of R/R/ CLL: Initiate Phase 3 head-to-head trial.

    2H 2025

    Lung Cancer

    • BGB-58067 (PRMT5 inhibitor) and BG-89894 (MAT2A inhibitor): First subject enrolled in combination trial.

    2H 2025

    Breast and Gynecologic Cancers

    • BGB-43395 (CDK4 inhibitor): Proof-of-concept data.

    1H 2025

    GI Cancers

    • Zanidatamab (HER2-bispecific antibody) for the treatment of first-line HER2-positive gastroesophageal adenocarcinoma: Readout of primary progression-free survival data from Phase 3 trial of in collaboration with Zymeworks/Jazz.

    2H 2025

    Inflammation and Immunology

    • BGB-45035 (IRAK4 CDAC): First subject enrolled in Phase 2 trial.

    2H 2025

     

    • BGB-45035: Proof-of-concept data for tissue IRAK4 degradation.

    2H 2025

    Other Highlights

    • Received shareholder approval on April 28, 2025, to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland with the transaction set to close later this year.
    • As previously disclosed, announced a U.S. Patent Trademark Office Final Written Decision invalidating all claims of Pharmacyclics LLC's U.S. Patent No. 11,672,803 that were challenged by BeiGene in a post-grant review (PGR) proceeding.
    • Appointed Marcello Damiani as Chief Technology Officer.

    Conference Call and Webcast

    The Company's earnings conference call for the first quarter 2025 will be broadcast via webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, and will be accessible through the Investors section of BeiGene's website, www.beigene.com. Supplemental information in the form of a slide presentation and a replay of the webcast will also be available.

    About BeiGene

    BeiGene, which will change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 11,000 colleagues spans six continents.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the anticipated milestones to be achieved by BeiGene in 2025; BeiGene's ability to become one of the world's most impactful oncology innovators; BeiGene's future revenue, operating income, cash flow, operating expenses and gross margin percentage; and BeiGene's plans, commitments, aspirations and goals under the caption "About BeiGene". Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene's ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeiGene's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law. BeiGene's financial guidance is based on estimates and assumptions that are subject to significant uncertainties.

    Condensed Consolidated Statements of Operations (U.S. GAAP)

     

    (Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs), per share and per ADS data)

     

     

    Three Months Ended

    March 31,

     

    2025

     

    2024

     

     

     

     

     

    (Unaudited)

    Revenues

     

     

     

    Product revenue, net

    $1,108,530

     

    $746,918

    Collaboration revenue

    8,749

     

    4,734

    Total revenues

    1,117,279

     

    751,652

    Cost of sales - products

    165,002

     

    124,935

    Gross profit

    952,277

     

    626,717

    Operating expenses:

     

     

     

    Research and development

    481,887

     

    460,638

    Selling, general and administrative

    459,288

     

    427,427

    Total operating expenses

    941,175

     

    888,065

    Income (loss) from operations

    11,102

     

    (261,348)

    Interest income, net

    5,848

     

    16,160

    Other income, net

    3,950

     

    1,762

    Income (loss) before income taxes

    20,900

     

    (243,426)

    Income tax expense

    19,630

     

    7,724

    Net income (loss)

    $1,270

     

    $(251,150)

     

     

     

     

    Earnings (loss) per share

     

     

     

    Basic

    $ 0.00

     

    $(0.19)

    Diluted

    $ 0.00

     

    $(0.19)

    Weighted-average shares outstanding—basic

    1,390,052,966

     

    1,355,547,626

    Weighted-average shares outstanding—diluted

    1,445,253,219

     

    1,355,547,626

     

     

     

     

    Earnings (loss) per American Depositary Share ("ADS")

     

     

     

    Basic

    $0.01

     

    $(2.41)

    Diluted

    $0.01

     

    $(2.41)

    Weighted-average ADSs outstanding—basic

    106,927,151

     

    104,272,894

    Weighted-average ADSs outstanding—diluted

    111,173,325

     

    104,272,894

    Select Condensed Consolidated Balance Sheet Data (U.S. GAAP)

     

    (Amounts in thousands of U.S. Dollars)

     

     

     

     

     

    As of

     

    March 31,

     

    December 31,

     

    2025

     

    2024

     

    (unaudited)

     

    (audited)

    Assets:

     

     

     

    Cash, cash equivalents and restricted cash

    $2,530,591

     

    $2,638,747

    Accounts receivable, net

    717,239

     

    676,278

    Inventories

    494,660

     

    494,986

    Property, plant and equipment, net

    1,598,588

     

    1,578,423

    Total assets

    5,841,526

     

    5,920,910

    Liabilities and equity:

     

     

     

    Accounts payable

    364,498

     

    404,997

    Accrued expenses and other payables

    692,179

     

    803,713

    R&D cost share liability

    145,628

     

    165,440

    Debt

    923,627

     

    1,018,013

    Total liabilities

    2,342,013

     

    2,588,688

    Total equity

    $3,499,513

     

    $3,332,222

    Select Unaudited Condensed Consolidated Statements of Cash Flows (U.S. GAAP)

     

    (Amounts in thousands of U.S. Dollars)

     

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

    2024

     

     

     

     

     

     

     

    (unaudited)

    Cash, cash equivalents and restricted cash at beginning of period

     

    $2,638,747

     

    $3,185,984

    Net cash provided by (used in) operating activities

     

    44,082

     

    (308,572)

    Net cash used in investing activities

     

    (121,941)

     

    (209,831)

    Net cash (used in) provided by financing activities

     

    (33,777)

     

    162,293

    Net effect of foreign exchange rate changes

     

    3,480

     

    (22,438)

    Net decrease in cash, cash equivalents, and restricted cash

     

    (108,156)

     

    (378,548)

    Cash, cash equivalents and restricted cash at end of period

     

    $2,530,591

     

    $2,807,436

    Note Regarding Use of Non-GAAP Financial Measures

    BeiGene provides certain non-GAAP financial measures, including Adjusted Operating Expenses Adjusted Operating Loss, Adjusted Net Income, Adjusted Earnings Per Share and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP financial measures are intended to provide additional information on BeiGene's operating performance. Adjustments to BeiGene's GAAP figures exclude, as applicable, non-cash items such as share-based compensation, depreciation and amortization. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Non-GAAP adjustments are tax effected to the extent there is US GAAP current tax expense. The Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects. BeiGene maintains an established non-GAAP policy that guides the determination of what costs will be excluded in non-GAAP financial measures and the related protocols, controls and approval with respect to the use of such measures. BeiGene believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of BeiGene's operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company's historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators BeiGene's management uses for planning and forecasting purposes and measuring the Company's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.

    RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES

     

    (Amounts in thousands of U.S. Dollars)

     

    (unaudited)

     

     

    Three Months Ended

     

    March 31,

     

    2025

     

    2024

     

     

    Reconciliation of GAAP to adjusted cost of sales - products:

     

     

     

    GAAP cost of sales - products

    $165,002

     

    $124,935

    Less: Depreciation

    2,613

     

    2,345

    Less: Amortization of intangibles

    1,173

     

    1,183

    Adjusted cost of sales - products

    $161,216

     

    $121,407

     

     

     

     

    Reconciliation of GAAP to adjusted research and development:

     

     

     

    GAAP research and development

    $481,887

     

    $460,638

    Less: Share-based compensation cost

    41,767

     

    38,045

    Less: Depreciation

    18,925

     

    17,153

    Adjusted research and development

    $421,195

     

    $405,440

     

     

     

     

    Reconciliation of GAAP to adjusted selling, general and administrative:

     

     

     

    GAAP selling, general and administrative

    $459,288

     

    $427,427

    Less: Share-based compensation cost

    53,684

     

    50,669

    Less: Depreciation

    10,076

     

    4,612

    Less: Amortization of intangibles

    17

     

    —

    Adjusted selling, general and administrative

    $395,511

     

    $372,146

     

     

     

     

    Reconciliation of GAAP to adjusted operating expenses

     

     

     

    GAAP operating expenses

    $941,175

     

    $888,065

    Less: Share-based compensation cost

    95,451

     

    88,714

    Less: Depreciation

    29,001

     

    21,765

    Less: Amortization of intangibles

    17

     

    —

    Adjusted operating expenses

    $816,706

     

    $777,586

     

     

     

     

    Reconciliation of GAAP to adjusted income (loss) from operations:

     

     

     

    GAAP income (loss) from operations

    $11,102

     

    $(261,348)

    Plus: Share-based compensation cost

    95,451

     

    88,714

    Plus: Depreciation

    31,614

     

    24,110

    Plus: Amortization of intangibles

    1,190

     

    1,183

    Adjusted income (loss) from operations

    $139,357

     

    $(147,341)

     

     

     

     

    Reconciliation of GAAP to adjusted net income (loss):

     

     

     

    GAAP net income (loss)

    $1,270

     

    $(251,150)

    Plus: Share-based compensation expenses

    95,451

     

    88,714

    Plus: Depreciation

    31,614

     

    24,110

    Plus: Amortization of intangibles

    1,190

     

    1,183

    Plus: Impairment of equity investments

    12,376

     

    —

    Plus: Income tax effect of non-GAAP adjustments

    (5,764)

     

    (8,753)

    Adjusted net income (loss)

    $136,137

     

    $(145,896)

     

     

     

     

    Reconciliation of GAAP to adjusted EPS - basic

     

     

     

    GAAP earnings (loss) per share - basic

    $0.00

     

    $(0.19)

    Plus: Share-based compensation expenses

    0.07

     

    0.07

    Plus: Depreciation

    0.02

     

    0.02

    Plus: Amortization of intangibles

    0.00

     

    0.00

    Plus: Impairment of equity investments

    0.01

     

    0.00

    Plus: Income tax effect of non-GAAP adjustments*

    (0.00)

     

    (0.01)

    Adjusted earnings (loss) per share - basic

    $0.10

     

    $(0.11)

     

     

     

     

    Reconciliation of GAAP to adjusted EPS - diluted

     

     

     

    GAAP earnings (loss) per share - diluted

    $0.00

     

    $(0.19)

    Plus: Share-based compensation expenses

    0.07

     

    0.07

    Plus: Depreciation

    0.02

     

    0.02

    Plus: Amortization of intangibles

    0.00

     

    0.00

    Plus: Impairment of equity investments

    0.01

     

    0.00

    Plus: Income tax effect of non-GAAP adjustments*

    (0.00)

     

    (0.01)

    Adjusted earnings (loss) per share - diluted

    $0.09

     

    $(0.11)

     

     

     

     

    Reconciliation of GAAP to adjusted earnings (loss) per ADS - basic

     

     

     

    GAAP earnings (loss) per ADS - basic

    $0.01

     

    $(2.41)

    Plus: Share-based compensation expenses

    0.89

     

    0.85

    Plus: Depreciation

    0.30

     

    0.23

    Plus: Amortization of intangibles

    0.01

     

    0.01

    Plus: Impairment of equity investments

    0.12

     

    0.00

    Plus: Income tax effect of non-GAAP adjustments*

    (0.05)

     

    (0.08)

    Adjusted earnings (loss) per ADS - basic

    $1.27

     

    $(1.40)

     

     

     

     

    Reconciliation of GAAP to adjusted earnings (loss) per ADS - diluted

     

     

     

    GAAP earnings (loss) per ADS - diluted

    $0.01

     

    $(2.41)

    Plus: Share-based compensation expenses

    0.86

     

    0.85

    Plus: Depreciation

    0.28

     

    0.23

    Plus: Amortization of intangibles

    0.01

     

    0.01

    Plus: Impairment of equity investments

    0.11

     

    0.00

    Plus: Income tax effect of non-GAAP adjustments*

    (0.05)

     

    (0.08)

    Adjusted earnings (loss) per ADS - diluted

    $1.22

     

    $(1.40)

    *Tax effect of Non-GAAP adjustments is based on the statutory tax rate in the relevant tax jurisdiction. Please note that the Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507583971/en/

    Investor Contact

    Liza Heapes

    +1 857-302-5663

    [email protected]

    Media Contact

    Kyle Blankenship

    +1 667-351-5176

    [email protected]

    Get the next $ONC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONC

    DatePrice TargetRatingAnalyst
    4/7/2025$312.00Outperform
    RBC Capital Mkts
    3/3/2025$207.00 → $320.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ONC
    Financials

    Live finance-specific insights

    See more
    • BeiGene Announces First Quarter 2025 Financial Results and Business Updates

      First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 Achieved GAAP profitability and significantly improved operating cash flow Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26 Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

      5/7/25 6:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene to Announce First Quarter 2025 Financial Results on May 7

      BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investors section of the Company's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the schedul

      4/17/25 6:01:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      Total global revenues of $1.1 billion and $3.8 billion for the fourth quarter and full year, increases of 78% and 55%, respectively; narrowed GAAP operating loss and achieved full-year positive non-GAAP operating income Global BRUKINSA revenues of $828 million and $2.6 billion for the fourth quarter and full year, increases of 100% and 105%, respectively; progressed pivotal-stage programs for BCL2 inhibitor sonrotoclax and BTK CDAC BGB-16673 Advanced six and 13 New Molecular Entities (NMEs) into the clinic in the fourth quarter and full year, respectively; anticipate multiple data readouts for innovative solid tumor programs in 1H 2025 Full year 2025 revenue guidance of $4.9 billi

      2/27/25 6:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BeiGene Announces First Quarter 2025 Financial Results and Business Updates

      First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 Achieved GAAP profitability and significantly improved operating cash flow Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26 Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

      5/7/25 6:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

      BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC's (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA® (zanubrutinib). On May 1, 2024, the USPTO grant

      4/29/25 3:32:00 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene to Announce First Quarter 2025 Financial Results on May 7

      BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investors section of the Company's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the schedul

      4/17/25 6:01:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chair, Scientific Advisory Brd Wang Xiaodong exercised 41,760 units of American Depositary Shares at a strike of $6.50 and sold $10,133,595 worth of American Depositary Shares (41,760 units at $242.66) (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      4/16/25 5:12:21 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, COO & GM China Wu Xiaobin exercised 51,921 units of American Depositary Shares at a strike of $157.14 and sold $14,610,370 worth of American Depositary Shares (51,921 units at $281.40) (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      4/3/25 5:04:54 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chair, Scientific Advisory Brd Wang Xiaodong exercised 41,760 units of American Depositary Shares at a strike of $6.50 and sold $10,911,252 worth of American Depositary Shares (41,760 units at $261.28) (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      3/20/25 4:53:28 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ONC
    SEC Filings

    See more
    • RBC Capital Mkts initiated coverage on BeiGene with a new price target

      RBC Capital Mkts initiated coverage of BeiGene with a rating of Outperform and set a new price target of $312.00

      4/7/25 8:43:36 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene upgraded by BofA Securities with a new price target

      BofA Securities upgraded BeiGene from Neutral to Buy and set a new price target of $320.00 from $207.00 previously

      3/3/25 7:35:01 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by BeiGene Ltd.

      10-Q - BeiGene, Ltd. (0001651308) (Filer)

      5/7/25 6:09:04 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BeiGene, Ltd. (0001651308) (Filer)

      5/7/25 6:04:56 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form F-6/A filed by BeiGene Ltd.

      F-6/A - BeiGene, Ltd. (0001651308) (Subject)

      5/1/25 4:06:10 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care